1. unable to obtain informed consent. 2. physician with more than 5 years of clinical experience determines that death was inevitable within 24 hours. 3. severe hepatic dysfunction (child pugh score ≥ c, or ast\> 5 times the upper limit); severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml/ min/1.73 m2) or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. uncontrolled hypertension (sitting systolic blood pressure\> 160mmhg, or diastolic blood pressure\>100mmhg); previous history of hypertension crisis or hypertensive encephalopathy. 5. poorly controlled heart diseases, such as nyha class ii and above cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia need treatment or intervention. 6. severe or above chronic obstructive pulmonary disease (gold grade, fev1/fvc \< 0.5). 7. hereditary bleeding tendency or coagulopathy; 8. arterial/venous thromboembolic events within 6 months before enrollment, such as ischemic stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, etc. severe vascular disease (including aneurysms or arterial thrombosis requiring surgery) within 6 months before enrollment. 9. unhealed wounds, active gastric ulcers or fractures. gastrointestinal perforation, gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6 months before enrollment. major surgery (including preoperative chest biopsy) or major trauma (such as a fracture) within 28 days before enrollment. may have surgery during the trial. 10. severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous system bleeding, and nosebleeds within 1 month before enrollment. 11. malignant tumors within 5 years before enrollment. 12. allergic to bevacizumab or its components. 13. active tuberculosis, uncontrollable infection, untreated active hepatitis or hiv-positive patients. 14. pregnant and lactating women and those planning to get pregnant. 15. participated in other clinical trials, not considered suitable for this study by the researchers.

1. unable to obtain informed consent. 2. physician with more than 5 years of clinical experience determines that death was inevitable within 24 hours. 3. severe hepatic dysfunction (child pugh score ≥ c, or ast\> 5 times the upper limit); severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml/ min/1.73 m2) or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. 4. uncontrolled hypertension (sitting systolic blood pressure\> 160mmhg, or diastolic blood pressure\>100mmhg); previous history of hypertension crisis or hypertensive encephalopathy. 5. poorly controlled heart diseases, such as nyha class ii and above cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia need treatment or intervention. 6. severe or above chronic obstructive pulmonary disease (gold grade, fev1/fvc \< 0.5). 7. hereditary bleeding tendency or coagulopathy; 8. arterial/venous thromboembolic events within 6 months before enrollment, such as ischemic stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, etc. severe vascular disease (including aneurysms or arterial thrombosis requiring surgery) within 6 months before enrollment. 9. unhealed wounds, active gastric ulcers or fractures. gastrointestinal perforation, gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6 months before enrollment. major surgery (including preoperative chest biopsy) or major trauma (such as a fracture) within 28 days before enrollment. may have surgery during the trial. 10. severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous system bleeding, and nosebleeds within 1 month before enrollment. 11. malignant tumors within 5 years before enrollment. 12. allergic to bevacizumab or its components. 13. active tuberculosis, uncontrollable infection, untreated active hepatitis or hiv-positive patients. 14. pregnant and lactating women and those planning to get pregnant. 15. participated in other clinical trials, not considered suitable for this study by the researchers.

unable to obtain informed consent. physician with more than 5 years of clinical experience determines that death was inevitable within 24 hours. severe hepatic dysfunction (child pugh score ≥ c, or ast> 5 times the upper limit); severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml/ min/1.73 m2) or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. uncontrolled hypertension (sitting systolic blood pressure> 160mmhg, or diastolic blood pressure>100mmhg); previous history of hypertension crisis or hypertensive encephalopathy. poorly controlled heart diseases, such as nyha class ii and above cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia need treatment or intervention. severe or above chronic obstructive pulmonary disease (gold grade, fev1/fvc < 0.5). hereditary bleeding tendency or coagulopathy; arterial/venous thromboembolic events within 6 months before enrollment, such as ischemic stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, etc. severe vascular disease (including aneurysms or arterial thrombosis requiring surgery) within 6 months before enrollment. unhealed wounds, active gastric ulcers or fractures. gastrointestinal perforation, gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6 months before enrollment. major surgery (including preoperative chest biopsy) or major trauma (such as a fracture) within 28 days before enrollment. may have surgery during the trial. severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous system bleeding, and nosebleeds within 1 month before enrollment. malignant tumors within 5 years before enrollment. allergic to bevacizumab or its components. active tuberculosis, uncontrollable infection, untreated active hepatitis or hiv-positive patients. pregnant and lactating women and those planning to get pregnant. participated in other clinical trials, not considered suitable for this study by the researchers.

unable to obtain informed consent. physician with more than 5 years of clinical experience determines that death was inevitable within 24 hours. severe hepatic dysfunction (child pugh score ≥ c, or ast> 5 times the upper limit); severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml/ min/1.73 m2) or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. uncontrolled hypertension (sitting systolic blood pressure> 160mmhg, or diastolic blood pressure>100mmhg); previous history of hypertension crisis or hypertensive encephalopathy. poorly controlled heart diseases, such as nyha class ii and above cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia need treatment or intervention. severe or above chronic obstructive pulmonary disease (gold grade, fev1/fvc < 0.5). hereditary bleeding tendency or coagulopathy; arterial/venous thromboembolic events within 6 months before enrollment, such as ischemic stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, etc. severe vascular disease (including aneurysms or arterial thrombosis requiring surgery) within 6 months before enrollment. unhealed wounds, active gastric ulcers or fractures. gastrointestinal perforation, gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6 months before enrollment. major surgery (including preoperative chest biopsy) or major trauma (such as a fracture) within 28 days before enrollment. may have surgery during the trial. severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous system bleeding, and nosebleeds within 1 month before enrollment. malignant tumors within 5 years before enrollment. allergic to bevacizumab or its components. active tuberculosis, uncontrollable infection, untreated active hepatitis or hiv-positive patients. pregnant and lactating women and those planning to get pregnant. participated in other clinical trials, not considered suitable for this study by the researchers.

unable to obtain informed consent. physician with more than 5 years of clinical experience determines that death was inevitable within 24 hours. severe hepatic dysfunction (child pugh score ≥ c, or ast> 5 times the upper limit); severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml/ min/1.73 m2) or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. uncontrolled hypertension (sitting systolic blood pressure> 160mmhg, or diastolic blood pressure>100mmhg); previous history of hypertension crisis or hypertensive encephalopathy. poorly controlled heart diseases, such as nyha class ii and above cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia need treatment or intervention. severe or above chronic obstructive pulmonary disease (gold grade, fev1/fvc < 0.5). hereditary bleeding tendency or coagulopathy; thrombosis within 6 months before enrollment. and from those patients, screen who had arterial / venous thromboembolic events, such as, ischemic stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, etc. within 1 year ahead of enrollment. severe vascular disease (including aneurysms or arterial thrombosis requiring surgery) within 6 months before enrollment. unhealed wounds, active gastric ulcers or fractures. gastrointestinal perforation, gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6 months before enrollment. major surgery (including preoperative chest biopsy) or major trauma (such as a fracture) within 28 days before enrollment. may have surgery during the trial. severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous system bleeding, and nosebleeds within 1 month before enrollment. malignant tumors within 5 years before enrollment. allergic to bevacizumab or its components. active tuberculosis, bacterial, fungal, or viral infection other than sars-cov-2, untreated active hepatitis or hiv-positive patients. pregnant and lactating women and those planning to get pregnant. participated in other clinical trials, not considered suitable for this study by the researchers.

unable to obtain informed consent. physician with more than 5 years of clinical experience determines that death was inevitable within 24 hours. severe hepatic dysfunction (child pugh score ≥ c, or ast> 5 times the upper limit); severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml/ min/1.73 m2) or receive continuous renal replacement therapy, hemodialysis, or peritoneal dialysis. uncontrolled hypertension (sitting systolic blood pressure> 160mmhg, or diastolic blood pressure>100mmhg); previous history of hypertension crisis or hypertensive encephalopathy. poorly controlled heart diseases, such as nyha class ii and above cardiac insufficiency, unstable angina pectoris, myocardial infarction within 1 year before enrollment, supraventricular or ventricular arrhythmia need treatment or intervention. severe or above chronic obstructive pulmonary disease (gold grade, fev1/fvc < 0.5). hereditary bleeding tendency or coagulopathy; thrombosis within 6 months before enrollment. and from those patients, screen who had arterial / venous thromboembolic events, such as, ischemic stroke, transient ischemic attack, deep venous thrombosis, pulmonary embolism, etc. within 1 year ahead of enrollment. severe vascular disease (including aneurysms or arterial thrombosis requiring surgery) within 6 months before enrollment. unhealed wounds, active gastric ulcers or fractures. gastrointestinal perforation, gastrointestinal fistula, abdominal abscess, visceral fistula formation within 6 months before enrollment. major surgery (including preoperative chest biopsy) or major trauma (such as a fracture) within 28 days before enrollment. may have surgery during the trial. severe, active bleeding such as hemoptysis, gastrointestinal bleeding, central nervous system bleeding, and nosebleeds within 1 month before enrollment. malignant tumors within 5 years before enrollment. allergic to bevacizumab or its components. active tuberculosis, bacterial, fungal, or viral infection other than sars-cov-2, untreated active hepatitis or hiv-positive patients. pregnant and lactating women and those planning to get pregnant. participated in other clinical trials, not considered suitable for this study by the researchers.

unable to obtain informed consent; patients with severe liver dysfunction (child pugh score ≥ c, or ast > 5 times of the upper limit), severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml / min / 1.73 m2), or continuous renal replacement therapy, hemodialysis, peritoneal dialysis; patients with hypertension and unsatisfactory control of antihypertensive drugs (sitting systolic blood pressure > 160mmhg, or diastolic blood pressure > 100mmhg) had a history of hypertension crisis or hypertensive encephalopathy; patients with heart disease or clinical symptoms that can not be well controlled, such as nyha class ii or above of cardiac insufficiency, unstable angina, myocardial infarction within one year, supraventricular or ventricular arrhythmias need treatment or intervention; those with known hereditary bleeding tendency or coagulation dysfunction, those who had received full dose anticoagulant or thrombolytic therapy in the first 10 days of the group, or those who had taken nonsteroidal anti-inflammatory drugs with platelet inhibition in the first 10 days of the group (except those who had preventive use of low-dose aspirin ≤ 325mg / day); in the first 6 months of the group, the patients who had thrombosis, such as ischemic stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism and other thrombotic diseases, and in the first 6 months of the group, the patients who had serious angiopathy (including aneurysms or arterial thrombosis requiring surgical treatment) were screened; patients with unhealed wounds, active gastric ulcer or fracture; patients with gastrointestinal perforation, gastrointestinal fistula, abdominal abscess and internal fistula in the first 6 months of the group; patients with major surgical history (including thoracotomy biopsy), major trauma (such as fracture) or possible surgery in the course of participating in the trial within 28 days before the group; there were hemoptysis, gastrointestinal bleeding, central nervous system bleeding, nose bleeding and other serious and active bleeding patients within one month before admission; there were malignant tumors in the past 5 years; those allergic to bevacizumab and its components; untreated active hepatitis patients and hiv positive patients; pregnant women, lactating women and planned pregnant women; have participated in other clinical trials or the researchers think it is not suitable to participate in this study.

unable to obtain informed consent; patients with severe liver dysfunction (child pugh score ≥ c, or ast > 5 times of the upper limit), severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml / min / 1.73 m2), or continuous renal replacement therapy, hemodialysis, peritoneal dialysis; patients with hypertension and unsatisfactory control of antihypertensive drugs (sitting systolic blood pressure > 160mmhg, or diastolic blood pressure > 100mmhg) had a history of hypertension crisis or hypertensive encephalopathy; patients with heart disease or clinical symptoms that can not be well controlled, such as nyha class ii or above of cardiac insufficiency, unstable angina, myocardial infarction within one year, supraventricular or ventricular arrhythmias need treatment or intervention; those with known hereditary bleeding tendency or coagulation dysfunction, those who had received full dose anticoagulant or thrombolytic therapy in the first 10 days of the group, or those who had taken nonsteroidal anti-inflammatory drugs with platelet inhibition in the first 10 days of the group (except those who had preventive use of low-dose aspirin ≤ 325mg / day); in the first 6 months of the group, the patients who had thrombosis, such as ischemic stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism and other thrombotic diseases, and in the first 6 months of the group, the patients who had serious angiopathy (including aneurysms or arterial thrombosis requiring surgical treatment) were screened; patients with unhealed wounds, active gastric ulcer or fracture; patients with gastrointestinal perforation, gastrointestinal fistula, abdominal abscess and internal fistula in the first 6 months of the group; patients with major surgical history (including thoracotomy biopsy), major trauma (such as fracture) or possible surgery in the course of participating in the trial within 28 days before the group; there were hemoptysis, gastrointestinal bleeding, central nervous system bleeding, nose bleeding and other serious and active bleeding patients within one month before admission; there were malignant tumors in the past 5 years; those allergic to bevacizumab and its components; untreated active hepatitis patients and hiv positive patients; pregnant women, lactating women and planned pregnant women; have participated in other clinical trials or the researchers think it is not suitable to participate in this study.

1. unable to obtain informed consent; 2. patients with severe liver dysfunction (child pugh score ≥ c, or ast > 5 times of the upper limit), severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml / min / 1.73 m2), or continuous renal replacement therapy, hemodialysis, peritoneal dialysis; 3. patients with hypertension and unsatisfactory control of antihypertensive drugs (sitting systolic blood pressure > 160mmhg, or diastolic blood pressure > 100mmhg) had a history of hypertension crisis or hypertensive encephalopathy; 4. patients with heart disease or clinical symptoms that can not be well controlled, such as nyha class ii or above of cardiac insufficiency, unstable angina, myocardial infarction within one year, supraventricular or ventricular arrhythmias need treatment or intervention; 5. those with known hereditary bleeding tendency or coagulation dysfunction, those who had received full dose anticoagulant or thrombolytic therapy in the first 10 days of the group, or those who had taken nonsteroidal anti-inflammatory drugs with platelet inhibition in the first 10 days of the group (except those who had preventive use of low-dose aspirin ≤ 325mg / day); 6. in the first 6 months of the group, the patients who had thrombosis, such as ischemic stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism and other thrombotic diseases, and in the first 6 months of the group, the patients who had serious angiopathy (including aneurysms or arterial thrombosis requiring surgical treatment) were screened; 7. patients with unhealed wounds, active gastric ulcer or fracture; patients with gastrointestinal perforation, gastrointestinal fistula, abdominal abscess and internal fistula in the first 6 months of the group; patients with major surgical history (including thoracotomy biopsy), major trauma (such as fracture) or possible surgery in the course of participating in the trial within 28 days before the group; 8. there were hemoptysis, gastrointestinal bleeding, central nervous system bleeding, nose bleeding and other serious and active bleeding patients within one month before admission; 9. there were malignant tumors in the past 5 years; 10. those allergic to bevacizumab and its components; 11. untreated active hepatitis patients and hiv positive patients; 12. pregnant women, lactating women and planned pregnant women; 13. have participated in other clinical trials or the researchers think it is not suitable to participate in this study.

1. unable to obtain informed consent; 2. patients with severe liver dysfunction (child pugh score ≥ c, or ast > 5 times of the upper limit), severe renal dysfunction (estimated glomerular filtration rate ≤ 30ml / min / 1.73 m2), or continuous renal replacement therapy, hemodialysis, peritoneal dialysis; 3. patients with hypertension and unsatisfactory control of antihypertensive drugs (sitting systolic blood pressure > 160mmhg, or diastolic blood pressure > 100mmhg) had a history of hypertension crisis or hypertensive encephalopathy; 4. patients with heart disease or clinical symptoms that can not be well controlled, such as nyha class ii or above of cardiac insufficiency, unstable angina, myocardial infarction within one year, supraventricular or ventricular arrhythmias need treatment or intervention; 5. those with known hereditary bleeding tendency or coagulation dysfunction, those who had received full dose anticoagulant or thrombolytic therapy in the first 10 days of the group, or those who had taken nonsteroidal anti-inflammatory drugs with platelet inhibition in the first 10 days of the group (except those who had preventive use of low-dose aspirin ≤ 325mg / day); 6. in the first 6 months of the group, the patients who had thrombosis, such as ischemic stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism and other thrombotic diseases, and in the first 6 months of the group, the patients who had serious angiopathy (including aneurysms or arterial thrombosis requiring surgical treatment) were screened; 7. patients with unhealed wounds, active gastric ulcer or fracture; patients with gastrointestinal perforation, gastrointestinal fistula, abdominal abscess and internal fistula in the first 6 months of the group; patients with major surgical history (including thoracotomy biopsy), major trauma (such as fracture) or possible surgery in the course of participating in the trial within 28 days before the group; 8. there were hemoptysis, gastrointestinal bleeding, central nervous system bleeding, nose bleeding and other serious and active bleeding patients within one month before admission; 9. there were malignant tumors in the past 5 years; 10. those allergic to bevacizumab and its components; 11. untreated active hepatitis patients and hiv positive patients; 12. pregnant women, lactating women and planned pregnant women; 13. have participated in other clinical trials or the researchers think it is not suitable to participate in this study.